[BIC-announce] Special Lecture by Dr. Nancy Richert: "An update on the findings in the TYSABRI-associated PML cases" (Mon-Apr-2nd, 8:30 am; de Grandpré Communications Centre, MNI)

[Zografos 'Aki' CARAMANOS]

Dear colleagues,

Please join us on Monday April-2nd, in the Neuro's de Grandpré
Communications Centre starting at 8:30 am for a discussion of the
differentiation of progressive multifocal leukoencephalopathy (*PML*) on
magnetic resonance imaging (*MRI*) by Dr. Nancy
Richert<http://f1000.com/thefaculty/member/6138466061268350> (Senior
Fellow in MS Clinical Development, Biogen Idec <http://www.biogenidec.com/>,
Cambridge).

Dr Richert’s presentation will be entitled “*An update on the findings in
the TYSABRI-associated PML cases*” and will cover the following important
topics aimed at improving PML outcome by early recognition:
*- Presentation of most recent data and cases*
*- Comparison of PML vs multiple sclerosis (MS) on MRI*
*- Demonstrate subtle findings in PML*
*- Discuss the use of frequent MRI scanning*

In order for us to be able to plan for refreshments please RSVP to Elinor
Tobman at ellie at mrs.mni.mcgill.ca as soon as possible.



*                *

*Biographical Sketch*

Dr Nancy Richert joined Biogen Idec as a Senior Fellow in MS Clinical
Development in 2010. Prior to this, Dr Richert was a Staff Clinician in
Neuroimmunology at the National Institute of Neurological Disorders and
Stroke (*NINDS*) within the National Institutes of Health (*NIH*) and a
Consultant in Diagnostic Imaging and Radiology at Children’s National
Medical Centre in Washington DC.

In addition, Dr Richert has served as a Member of the National MS Society’s
(*NMSS*) Scientific Peer Review Committee (2003 – 2007). She is also a
member of the NMSS Task Force for Nervous System Repair.

Dr Richert’s primary specialty is in imaging in MS including magnetic
resonance imaging (*MRI*) and magnetisation transfer ratios (*MTR*).  Over
the past 14 years her work has advanced the development and application of
MRI outcome measures of disease activity in MS. Dr Richert’s work in
clinical trials includes measurements and predictors of brain atrophy. She
has participated in several clinical trials for interferonβ-1b,
Insulin-like growth factor, altered peptide ligand, and most recently
daclizumab.

Dr Richert has had extensive involvement as a scientific and medical
reviewer for journals including Neurology, Multiple Sclerosis and Annals of
Neurology



-- 
Zografos Caramanos, M.A.

Research Assistant, Magnetic Resonance Spectroscopy Unit
Ph.D. Student, Integrated Program in Neuroscience

McConnell Brain Imaging Centre,
Montreal Neurological Institute, McGill University
3801 University Street, Montreal, Quebec, Canada, H3A 2B4
(phone) 514-299-8160;  (fax) 514-398-2975
(e-mail) zografos.caramanos at mcgill.ca
(website) www.zcaramanos.com
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://www.bic.mni.mcgill.ca/pipermail/bic-announce/attachments/20120326/83b4ca44/attachment.htm>